Vanqua Bio

Neurology & CNS Therapeutics
$136Mtotal raised · 3 rounds on record
$45Mlatest round · Venture round · Feb 2024 · 2 yr ago
3backers · Omega Funds, OrbiMed
200+team · employees, estimated range

Overview

Our Mission. Deliver medicines that transform the lives of patients with neurodegenerative diseases.

Funding and backers

Total raised
$136M
3 rounds on record
Latest round
$45M
Venture round · Feb 2024 · 2 yr ago
Team
201-500
employees, estimated range
Backers
3
Omega Funds, OrbiMed
The money's age
Long since its last round
32 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 15, 2024 Raised a round Venture round $45M · SEC Form D Aug 27, 2021 Raised a round Venture round $85M · SEC Form D Sep 20, 2019 Raised a round Venture round $6M · SEC Form D 2019 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Feb 2024 $45M — SEC Form D
Venture round Aug 2021 $85M — SEC Form D
Venture round Sep 2019 $6M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity VANQUA BIO, INC. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Viola MeehanExecutive OfficerSEC Form D
James SullivanExecutive Officer, DirectorSEC Form D
Jonathan SilversteinDirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Omega Funds fund OrbiMed fund Pontifax fund
Investors in similar startupsfunds that back the companies most like this one
SOSV
backs Neurocarrus
Lux Capital
backs Cajal Tx
M Ventures
backs NRG Therapeutics
Twin Path Ventures
backs Sentinal 4D
BioGeneration Ventures
backs VectoryTx
Charlottesville Angel Network
backs Actuated Medical
Similar startupsby what they do, their industry and backers
VectoryTxFounded 2020 · 51-200 employees · 1 role
A biotech company dedicated to developing transformative medicines for people with neurodegenerative diseases using cutting-edge science…
TrueBindingVenture round $57.7M · 3 yr ago · 51-200 employees
Founded in 2016, TrueBinding Inc. is a clinical stage biotherapeutic company creating new and exciting molecules for applications in…
NRG TherapeuticsVenture round · 8 mo ago · Founded 2018 · 201-500 employees
Restoring energy. Next-generation disease-modifying medicines for ALS and Parkinson's.
NeurocarrusFounded 2017 · 11-50 employees
What is Neurocarrus?Treating Neurodegenerative Disease and Pain Without Addiction.Neurocarrus is a biotech company developing a novel drug…
Nine Square Therapeutics
Accelerating the development of better drugs for better targets in a quest to alter the trajectory of neurodegenerative disease.
Cajal Tx201-500 employees
Advancing medicines to restore homeostasis. Cajal Therapeutics is developing novel medicines for serious diseases, including anemias of…

Financials

Total raised
$136M
Latest round
Venture - Series Unknown
Funding rounds
3
Funding rounds
Round Announced Amount
Venture - Series Unknown 2024 $45M Details
Venture - Series Unknown 2021 $85M Details
Venture - Series Unknown 2019 $6M Details

People

Viola Meehan
Executive Officer
SEC Form D
James Sullivan
Executive Officer, Director
SEC Form D
Jonathan Silverstein
Director
SEC Form D
Mona Ashiya
Director
SEC Form D
Bernard Davitian
Director
SEC Form D
Sara Nayeem
Director
SEC Form D
Stephen Squinto
Director
SEC Form D
Rand Sutherland
Director
SEC Form D
Uya Chuluunbaatar
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Connections

List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors3
PontifaxVia a fund
55 portfolio companies: Climb Bio, CadenSee, Crystalys Therapeutics - Passionate. Dedicated. We improve lives. and 52 more
Omega FundsVia a fund
160 portfolio companies: Windward Bio, Xiimedical, Xtuit and 157 more
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Report a mistake

News

Blog 6 months ago
Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences
CHICAGO, May 19, 2026 (GLOBE NEWSWIRE) - Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim data from its Phase 1b study at World Parkinson's Congress and the GBA1 Meeting 2026, both taking place in Pho
Read more
Report
Press release The Manila Times 6 months ago
Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences
CHICAGO, May 19, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim data from its Phase 1b study at World Parkinson's Congress and the GBA1 Meeting 2026, both taking place in Ph
Read more
Report
Blog 8 months ago
Vanqua Bio to Present at the AD/PD 2026 International Conference
CHICAGO, March 12, 2026 (GLOBE NEWSWIRE) - Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PDTM 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders,
Read more
Report
Press release The Manila Times 8 months ago
Vanqua Bio to Present at the AD/PD 2026 International Conference
CHICAGO, March 12, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PDTM 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Read more
Report
News bioworld.com 1 year ago
Vanqua Bio Inc. - Page 1 BioWorld
BioWorld Content on
Read more
Report
Blog 1 year ago
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) - Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. This agreement strength
Read more
Report
News markets.ft.com 1 year ago
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Blog 1 year ago
Vanqua Bio Highlights Positive Interim Data from its Ongoing Phase 1b Clinical Trial of VQ-101, an Allosteric Activator of GCase for the Treatment of GBA-Parkinson's and Related Disorders, at The International Congress of Parkinson's Disease and Movement Disorders
CHICAGO, Oct. 02, 2025 (GLOBE NEWSWIRE) - Vanqua Bio, a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced positive interim results from the
Read more
Report
Blog 1 year ago
Vanqua Bio to Present at Upcoming Scientific Conferences
CHICAGO, June 03, 2025 (GLOBE NEWSWIRE) - Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its lead clinical program, VQ-101, at two upcoming scientific conferences - the GBA1 Meeting
Read more
Report
News YahooFinance 1 year ago
Vanqua Bio to Present at Upcoming Scientific Conferences
CHICAGO, June 03, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its lead clinical program, VQ-101, at two upcoming scientific conferences - the GBA1 Meetin
Read more
Report
Show more news

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Chicago United States
HQ
200-500 est. staff